Търсене на изпитвания

Намерени 4,436 изпитвания Стр. 174 от 222

Набира участници Фаза 1

Pilot Imaging Study of Leukemia

Acute Lymphocytic Leukemia Acute Myeloid Leukemia Ambiguous Lineage Leukemia or Lymphoma Myeloma

This is a prospective pilot study, the primary aim of which is to determine whether the presence of 18F FLT imaging signal uptake abnormalities correlate with clinically validated evidence of hematopoietic malignant disease (e.g. MRD, molecular, flow or histology) after immunotherapy and other treatments.

Начало: 19.01.2023 Край: 01.04.2029 Възраст: 4–80 г.

United States University of Oklahoma NCT03633955

Набира участници

Evaluation of the Clinical Outcomes of the Total Knee ps Prosthesis Implanted With the Use of Inertial Sensors

Prosthesis Durability

evaluate the clinical outcome of the implantation of a specific primary TKA model implanted with the aid of inertial sensors for the execution of bone cuts through the administration of questionnaires for the calculation of clinical-functional scores;

Начало: 13.01.2023 Край: 01.03.2027 Възраст: 50–85 г.

Italy Istituto Ortopedico Rizzoli NCT06321042

Набира участници Фаза 1

FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3

Urinary Bladder Neoplasms Neoplasm Metastasis Ureteral Neoplasms

The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-435 by itself or when it is combined with other standard medicines that treat cancer. LOXO-435 may be used to treat cancer of the cells that line the urinary system and other solid tumor cancers that have a change in a particular gene (known as the FGFR3 gene). Participation could last up to 30 months (2.5 years) and possibly longer if the disease does not get worse.

Начало: 12.01.2023 Край: 01.06.2027 Възраст: от 18 г. Лечение

Australia, Canada, China +11 Eli Lilly and Company NCT05614739

Набира участници

Satisfaction and Recovery After Distal Radius Fracture

Distal Radius Fracture

Distal radius fracture is the most common fracture in Sweden, but little is known about the patient's experience of pain and hand function during the first three months after the injury. This observational study will provide detailed information on a daily basis regarding pain, use of analgesic drugs, use of splints and hand function as measured weekly by a condition-specific questionnaire.

Начало: 12.01.2023 Край: 01.04.2028 Възраст: от 18 г.

Sweden Sahlgrenska University Hospital NCT05818241

Набира участници Фаза 2

A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease

Sickle Cell Disease

This study is being done to learn about etavopivat, a once a day medicine taken by mouth in adolescents with sickle cell disease. The main goals are to study safety and how long etavopivat stays in the bloodstream, while also studying if there are benefits from taking etavopivat. Eligible participants who enter the study will start a 96-week treatment period. At the end of the 96 weeks, participants will have an end of study visit that occurs 4 weeks later. The participants will receive etavopivat every day throughout the treatment period.

Начало: 12.01.2023 Край: 08.08.2029 Възраст: 6–18 г.

Canada, France, Kenya +4 Forma Therapeutics, Inc. NCT06198712

Набира участници Фаза 1

Dose Escalation and Expansion Study of HM97662 in Advanced or Metastatic Solid Tumors

Advanced or Metastatic Solid Tumors

This is a Phase1 study to assess the safety, PK, PD and efficacy of HM97662, EZH1/2 dual inhibitor, in solid tumors. The study is comprised of Dose-Escalation Part followed by randomized Dose-Ranging Part and Dose-Expansion Part. Dose-Escalation Part is planned with a 3+3 Dose-Escalation design and is to establish the MTD or RD for randomized Dose-Ranging Part. Dose-Ranging Part is designed mainly to further evaluate safety and preliminary efficacy of HM97662 monotherapy in subjects with specific genomic alterations to more precisely determine the potential RP2D that are to be tested in a Dose-Expansion Part. Dose-Expansion Part is designed to assess the potential efficacy of HM97662 monotherapy when administered at the RP2D to subjects in indication-specific expansion cohorts.

Начало: 11.01.2023 Край: 01.06.2028 Възраст: от 18 г. Лечение

Australia, South Korea Hanmi Pharmaceutical Company Limited NCT05598151

Набира участници

Preventive Physical Activity Intervention in Head and Neck Cancer

Head and Neck Neoplasms Physical Inactivity

The study includes patients with tumors of the oropharynx, larynx and hypopharynx scheduled to receive radiotherapy with curative intent (+/- chemotherapy). The patients will be randomized into either an intervention group (performing a preventive physical activity protocol before and during radiotherapy) or a control group not performing a specified physical exercise protocol. All patients will be in contact with with a speech language pathologist or a physical therapist weekly during radiotherapy. The study is expected to improve physical function and quality of life during and after oncologic treatment

Начало: 02.01.2023 Край: 01.12.2032 Възраст: от 18 г.

Sweden Sahlgrenska University Hospital NCT05432297

Набира участници

Ambispective Multicentric Study Evaluating UKA With U-Knee/Uni-Kroma Implants

Unicompartmental Knee Arthroplasty

This clinical investigation was led as a post-market clinical follow-up study (post-market device development stage).The main objective of this study is to collect short- and medium-term clinical data on the unicondylar knee prosthesis U-Knee / Uni-Kroma, in order to evaluate the performance of these implants.

Начало: 01.01.2023 Край: 31.01.2035 Възраст: от 18 г.

France Societe dEtude, de Recherche et de Fabrication NCT05876143

Набира участници

Comparative Effectiveness of Online 8-session CBT vs. 1-Session Empowered Relief for Chronic Pain - The PROGRESS Study

Pain, Chronic Lupus Pelvic Pain

The purpose of this study is to conduct a pragmatic clinical trial comparing the effectiveness of: (1) 8-week cognitive behavioral therapy for chronic pain (pain-CBT; sixteen hours total treatment time); and (2) a 1-session pain relief skills intervention for chronic pain (Empowered Relief; two hours total treatment time).

Начало: 01.01.2023 Край: 01.05.2029 Възраст: от 18 г.

United States Stanford University NCT05612750

Набира участници

Evaluation and Further Development of an Artificial Intelligence-based Algorithm for Clinical Decision Support

Invasive Mechanical Ventilation

Invasive mechanical ventilation is one of the most important and life-saving therapies in the intensive care unit (ICU). In most severe cases, extracorporeal lung support is initiated when mechanical ventilation is insufficient. However, mechanical ventilation is recognised as potentially harmful, because inappropriate mechanical ventilation settings in ICU patients are associated with organ damage, contributing to disease burden. Studies revealed that mechanical ventilation is often not provided adequately despite clear evidence and guidelines. Variables at the ventilator and extracorporeal lung support device can be set automatically using optimization functions and clinical recommendations, but the handling of experts may still deviate from those settings depending upon the clinical characteristics of individual patients. Artificial intelligence can be used to learn from those deviations as well as the patient's condition in an attempt to improve the combination of settings and accomplish lung support with reduced risk of damage.

Начало: 01.01.2023 Край: 01.09.2026 Възраст: от 18 г.

Germany, Serbia, Spain +2 Technische Universität Dresden NCT05668637

Набира участници Фаза 3

SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 Diabetes

Type 2 Diabetes

The aim of the trial is to evaluate the effects of the SGLT2 inhibitor, dapagliflozin, compared to metformin on annual decline in eGFR when used as first line therapy in people with Type 2 Diabetes.

Начало: 01.01.2023 Край: 30.06.2026 Възраст: от 18 г. Превенция

Australia, Sri Lanka The George Institute NCT05345327

Набира участници

SSVEP Evaluation of Brain Function (PRO)

Mild Traumatic Brain Injury

The investigational device used in this clinical investigation, the Nurochek PRO System (NCPRO), is a portable electroencephalogram (EEG) headset which delivers a visual stimulus and measures a VEP. The visual stimulus is delivered to the subjects' eyes via light-emitting diodes, and the EEG measures the user's visual-evoked potential. This headset communicates with an application on a computer, which processes the signals and transmits them to a secure cloud server for analysis and storage of the data. Nurochek PRO is a development of the previously FDA cleared Nurochek System. The primary objective of this clinical investigation was to evaluate the performance of the investigational device (NCPRO) against clinical diagnosis of detection of mild traumatic brain injury (mTBI). The primary endpoint outlined for this study was set at the collection of 100 valid investigational device readings from individuals with concussion and 500 valid investigational device readings from healthy individuals who have had a plausible mechanism of sustaining a concussion, but do not have one. Additionally, readings from healthy individuals are also to be acquired. The aim of this study was to collect data from 100 readings from individuals with concussion. The initial assumption was that sites would provide players pre-season and make players available for testing post-concussion. In practice, some sites provided player data only post-concussion event (such as medical clinics). Participants were acquired from sporting clubs, medical clinicals and schools.

Начало: 01.01.2023 Край: 01.01.2026 Възраст: от 12 г.

Australia Headsafe MFG NCT06013566

Набира участници

Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy

Hematologic Malignancy Blood Cancer Lymphoma Leukemia +1

The goal of this study is to determine whether a palliative care intervention (PEACE) can improve the quality of life and experiences of participants with Lymphoma, Leukemia, or Multiple Myeloma receiving adoptive cellular therapy (ACT). After completion of an open pilot, participants will be randomly assigned into one of two study intervention groups. The names of the study intervention groups involved in this study are: * Palliative care (PEACE) plus usual oncology care * Usual care (standard oncology care) Participation in this research study is expected to last for up to 2 years. It is expected that about 90 people will take part in this research study.

Начало: 30.12.2022 Край: 01.04.2027 Възраст: от 18 г.

United States Massachusetts General Hospital NCT05646576

Набира участници Фаза 3

A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease (COPD)

This study will evaluate the efficacy and safety of astegolimab compared with placebo in participants with chronic obstructive pulmonary disease (COPD) who are former or current smokers and have a history of frequent exacerbations.

Начало: 29.12.2022 Край: 24.09.2027 Възраст: 40–80 г. Лечение

Argentina, Australia, Belgium +32 Hoffmann-La Roche NCT05595642

Набира участници Фаза 3

Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively

Hemophilia A Hemophilia B

A study to learn about the long-term safety and efficacy of giroctocogene fitelparvovec or fidanacogene elaparvovec in patients with hemophilia A or hemophilia B respectively, who have received treatment through prior participation in a Pfizer-sponsored clinical trial. Data collection and participant visits will be based on standard of care.

Начало: 28.12.2022 Край: 25.02.2040 Възраст: от 18 г. Друго

Australia, Taiwan, Turkey (Türkiye) +1 Pfizer NCT05568719

Набира участници Фаза 1

Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma

B Cell Lymphoma Aggressive Lymphoma Diffuse Large B Cell Lymphoma High-grade B-cell Lymphoma +2

This phase 1 pilot study examines the feasibility and safety of mosunetuzumab after autologous stem cell transplant for patients with aggressive B cell lymphomas. Mosunetuzumab is an antibody that has been engineered to attach to two target cells in the immune system: T cells that normally perform tasks like killing virus-infected cells, and cancerous B cells. Mosunetuzumab has been designed to direct these T cells to kill the cancerous B cells instead.

Начало: 22.12.2022 Край: 31.08.2028 Възраст: от 18 г.

United States Washington University School of Medicine NCT05412290

Набира участници

Metastatic Leiomyosarcoma Biomarker Protocol

Leiomyosarcoma

Leiomyosarcoma (LMS) is one of the most prevalent soft tissue sarcomas (STS) and can occur in various sites including soft tissue, uterus and retroperitoneal large vessels. Metastatic disease occurs in approximately 50% of patients diagnosed with leiomyosarcoma and prognosis is poor in setting of metastatic disease. A minority of patients benefit from treatment with chemotherapy and early biomarkers of benefit from treatment are lacking. A biomarker of tumor response and patient survival benefit from chemotherapy early in the course of chemotherapy would be of significant impact in treatment planning. Circulating tumor DNA (ctDNA) is present in blood of patients with advanced/metastatic cancer and may serve as biomarker of tumor response to chemotherapy. Blood samples will be collected prior to and during and chemotherapy, and analyzed for ctDNA and for mutations in genes that are associated with increased risk of developing sarcoma. Tumor tissue will be collected and analyzed for changes in genes. Digital images of the sarcoma from CT or MRI scans obtained during treatment will be obtained for advanced radiomic analysis. Study participants will be asked to complete a questionnaire on attitudes and understanding of genetics and genetic testing.

Начало: 22.12.2022 Край: 01.12.2026

Australia, United States University of Michigan Rogel Cancer Center NCT05653388

Набира участници Фаза 1/2

A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of SLC-3010 Monotherapy and in Combination

Advanced Solid Tumor

This is a Phase 1/2, open-label, multicenter, dose escalation and expansion study, evaluating the safety, tolerability, pharmacokinetic, preliminary anti-tumor activity, and effects on pharmacodynamic markers following administration of SLC-3010 as monotherapy and in combination with gemcitabine, in patients with various advanced solid tumors.

Начало: 21.12.2022 Край: 01.01.2028 Възраст: от 18 г. Лечение

Australia, South Korea, United States Selecxine NCT05525247

Набира участници Фаза 3

COLchicine and Non-enteric Coated Aspirin in the Cardiovascular Outcomes Trial of Patients With Type 2 Diabetes

Diabete Type 2 Cardiovascular Diseases

To evaluate the efficacy and safety of colchicine and non-enteric coated aspirin, combined or alone, to improve cardiovascular outcomes in high-risk patients with type 2 diabetes.

Начало: 21.12.2022 Край: 01.12.2027 Възраст: 55–80 г. Превенция

Australia, Canada, Denmark +5 Montreal Heart Institute NCT05633810

Набира участници

European Myeloma Network (EMN) Sample Project

Multiple Myeloma Smoldering Multiple Myeloma Plasma Cell Leukemia Extramedullary Myeloma +1

This is an observational, non-interventional, multicenter study for the prospective collection, storage and analysis of patients' biological samples. This study establishes a common international infrastructure useful to collect standard clinical variables at baseline and during treatment and to uniformly collect and store biological samples

Начало: 21.12.2022 Край: 01.12.2037 Възраст: от 18 г.

Australia, Belgium, Czechia +6 European Myeloma Network B.V. NCT06237803

1 … 172 173 174 175 176 … 222